Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

SOPHiA Genetics partners with AstraZeneca on diagnostics

5 August 2026 · By · Wire by Fusion42

Published

5 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Source

Read at vir.com.vn →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

SOPHiA Genetics has entered a global collaboration with AstraZeneca to develop and deploy two companion diagnostics supporting precision oncology therapies, aiming to enable local lab testing globally from day one of drug approval.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 3 sources have reported it between 4 Aug 2026 and 5 Aug 2026.

◆ ◆ The Wire takeaway

You can now sell diagnostic technology that launches worldwide alongside new AstraZeneca therapies. This partnership opens direct access to local labs needing instant reliable tests, cutting time to market for your solutions.

◆ Coverage

3 sources · first reported 4 Aug 2026 · latest 5 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsprecision-oncologycompanion-diagnosticspharma-collaborationdecentralized-testingAI-powered